The IPO window has been mostly closed, but there is a huge amount of capital available in private markets; does this rhyme with how the tech unicorns of the aughts came about? Read more on this in the Driehaus Life Sciences team's latest one-pager, "What's Up In Private Markets?".
Emerging Market (EM) equities began the year on strong footing, with China leading the way, while Indian equities were relative laggards. This month’s commentary examines whether the China-India trade-off that many investors undertook throughout 2022 will continue to persist.
Featured Commentary
What's Up In Private Markets?
By US Growth Equities
The IPO window has been mostly closed, but there is a huge amount of capital available in private markets; does this rhyme with how the tech unicorns of the aughts came about? Read more on this in the Driehaus Life Sciences team's latest one-pager, "What's Up In Private Markets?".
Driehaus Emerging Markets Small Cap Equity Strategy January 2023 Commentary
By Chad Cleaver, CFA
Emerging Market (EM) equities began the year on strong footing, with China leading the way, while Indian equities were relative laggards. This month’s commentary examines whether the China-India trade-off that many investors undertook throughout 2022 will continue to persist.